Dr. Iqbal is Director of the Microarray CGH laboratory, Director of Clinical Cytogenetics development and Associate Director of the Cytogenetics Laboratory. He has extensive experience and expertise in molecular cytogenetics, including a novel technology, array Comparative Genomic Hybridization (array CGH). This approach is more rapid and quantitative than conventional cytogenetics. The laboratory has recently begun to offer reference clinical testing for the New York State area, being one of the first three laboratories approved by New York State to do this testing. He has established an international leadership role in this area, serving as a core facility for array CGH consortia focused on specific diagnostic issues.
Dr. Iqbal is a member of the steering committee of the Cancer Cytogenomics Microarray Consortium (CCMC) - http://www.urmc.rochester.edu/ccmc/ - which was established to promote communication and collaboration among cancer cytogenetics laboratories.
Dr. Iqbal's research is in the area of clinical and molecular cytogenetics. He has a particular interest in the application of cytogenetic and FISH testing in the diagnosis of neoplastic as well as genetic disorders. His interests include the molecular cytogenetics of renal cell carcinoma, small round cell tumors, the cytogenetics of leukemia and lymphomas, and prenatal cytogenetic diagnostics. He has special interest in cryptic rearrangements involving subtelomere regions of human chromosomes in genetic disorders and leukemia. Dr. Iqbal is actively involved in bringing microarray technology into use as the next cytogenomics tool to translate lab innovations into postnatal, prenatal and cancer diagnosis.
BS | India-Osmania U, Gandhi Med Coll
MS | India-Osmania U, Gandhi Med Coll
PhD | India-Osmania U, Gandhi Med Coll
2010 - 2011
Sponsor: American College of Medical Genetics Foundation
"Assessing copy number abnormalities and copy-neutral loss-of-heterozygosity across the genome as best practice in diagnostic evaluation of acute myeloid leukemia: An evidence-based review from the cancer genomics consortium (CGC) myeloid neoplasms working group." Cancer genetics.. 2018 Dec 0; 228-229:218-235. Epub 2018 Oct 06.
Kanagal-Shamanna R, Hodge JC, Tucker T, Shetty S, Yenamandra A, Dixon-McIver A, Bryke C, Huxley E, Lennon PA, Raca G, Xu X, Jeffries S, Quintero-Rivera F, Greipp PT, Slovak ML, Iqbal MA, Fang M. "Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms." Cancer genetics.. 2018 Dec 0; 228-229:197-217. Epub 2018 Oct 10.
Reyes Barron C, Evans AG, Miyamoto H, Zhang B, Iqbal MA. "Novel 1.3 Mb germline duplication in chromosome 8q21.11 by microarray comparative genomic hybridization plus single nucleotide polymorphism analysis in an adult patient with pancytopenia and urinary bladder complications." Clinical case reports.. 2018 Oct 0; 6(10):1947-1952. Epub 2018 Aug 16.
VIEW ALL PUBLICATIONS